ArticleVeterinary sciences2026
The Paradox of Availability: A Quantitative Analysis of Veterinary Medicinal Products for Aquaculture in Europe Between 2018 and 2026.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Availability of veterinary medicinal products is a critical determinant of health, welfare, and economic sustainability in European aquaculture. This study assessed the changes in the authorization and reported market availability of veterinary medicines for finfish in the European Union (EU) and European Free Trade Association (EFTA) between 2018 and 2026, by comparing and analyzing data on veterinary medicinal products for aquatic species from the Heads of Medicines Agencies (HMA), the FishMedPlus Coalition, and the European Medicines Agency Union Product Database. The results revealed a wide divergence between regulatory authorization and reported availability. While the total number of authorized VMPs nominally increased from 304 in 2018 to 332 in 2025 (+9.2%), the number of reported unique active substances available declined (-16.7%). Crucially, the analysis of 2025 data indicates that only 26.5% of authorized products were reported to be actively available on the market, creating a "paper market" that masks severe therapeutic gaps, particularly in minor fish species such as seabass, seabream, carp, and trout sectors. Potential key drivers identified were limited markets, industry consolidation, increased burden related to stricter environmental requirements, as well as enlarged administrative and financial burdens. Despite EU legislative mechanisms designed to support limited markets, the sector faces stagnation in therapeutic diversity, necessitating continued reliance on the off-label use of medicines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.